Artificial Intelligence
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
LONDON and SAN FRANCISCO, Dec. 17, 2021 (GLOBE NEWSWIRE) — GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Commission (EC) has granted marketing authorization to Xevudy (sotrovimab) for the early treatment of COVID-19. Sotrovimab is now approved in the European Union (EU) for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40kg) with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.
The grant of the marketing authorization in the EU is a result of the positive opinion issued on December 16 by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).
In July 2021, GSK and Vir announced a Joint Procurement Agreement (JPA) with the EC to supply up to 220,000 doses of sotrovimab. Following the grant of the marketing authorization in the EU, Member States participating in the JPA can now order sotrovimab to support their pandemic responses.
Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said: “Since the start of the pandemic we have seen an unprecedented effort by governments, academia and industry to find solutions to help as many people as quickly as possible. COVID-19 therapeutics are an important part of the solution. We have already been working to lay the foundation for more patients across Europe to access sotrovimab through the Joint Procurement Agreement with the European Commission. With today’s marketing authorization we are now able to expand access, and we are discussing with governments how we can bring sotrovimab to more patients.”
George Scangos, Ph.D., Chief Executive Officer of Vir, said: “The grant of the marketing authorization in the European Union for sotrovimab marks yet another important milestone in our efforts to combat COVID-19, as it allows us to expand access across multiple countries working to address this challenge. Given recent preclinical data from our own labs, as well as that of other independent labs, demonstrating that sotrovimab retains activity against the rapidly spreading Omicron variant and all other currently tested variants of concern and interest, we remain confident in the critical role of sotrovimab and look forward to further contributing to the fight against this pandemic.”
The grant of the marketing authorization in the EU is based on data from the COMET-ICE Phase 3 trial, demonstrating that intravenous treatment with sotrovimab resulted in a 79% reduction (adjusted relative risk reduction) (p<0.001) in all-cause hospitalizations for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. In absolute numbers, 30 (6%) of the 529 patients in the placebo arm progressed, compared to six (1%) of the 528 patients receiving sotrovimab. In clinical trials conducted to date, sotrovimab has been well-tolerated. The most common adverse reactions are hypersensitivity and infusion-related reactions, seen in approximately 2% and 1% of cases, respectively.
GSK and Vir are committed to the ongoing evaluation of sotrovimab as the COVID-19 landscape continues to evolve at different rates across the globe and new variants of concern and interest emerge. Updated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against all tested variants of concern and interest of the SARS-CoV-2 virus as defined by the World Health Organization, including, but not limited to, Omicron (B.1.1.529), Delta (B.1.617.2), Delta Plus (AY.1 or AY.2) and Mu (B.1.621).
About Xevudy (Sotrovimab)
Xevudy (sotrovimab) is an investigational SARS-CoV-2 neutralizing monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS), indicating that the epitope is highly conserved, which may make it more difficult for resistance to develop. Sotrovimab, which incorporates Xencor, Inc.’s Xtend™ technology, has also been designed to achieve high concentration in the lungs to ensure optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life.
About Global Access to Sotrovimab
Sotrovimab is authorized for emergency use in the US. Xevudy (sotrovimab) has been granted a Marketing Authorization in the EU, conditional marketing authorization in Great Britain, provisional marketing authorization in Australia, and conditional marketing authorization in Saudi Arabia. It has also been approved via Japan’s Special Approval for Emergency Pathway. Temporary authorizations for sotrovimab have been granted in 12 other countries.
Sotrovimab is supplied in several countries worldwide, including through national agreements in the US, UK, Japan, Australia, Canada, Singapore, Switzerland and the United Arab Emirates. The companies have also announced a JPA with the EC to supply doses of sotrovimab to participating Member States of the EU. Additional agreements are yet to be disclosed due to confidentiality or regulatory requirements.
Important Information About Sotrovimab in the European Union
For more information on the marketing authorization in the European Union, please review the Summary of Product Characteristics (SmPC). Healthcare professionals should look out for side effects and take appropriate action.
Reporting of Suspected Adverse Reactions
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Warnings and Precautions
Hypersensitivity Reactions including Anaphylaxis
Hypersensitivity reactions, including anaphylaxis, have been reported with administration of sotrovimab (see section 4.8 of the SmPC). If signs or symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, administration should be discontinued immediately and appropriate medications and/or supportive care should be given.
Infusion-Related Reactions
Infusion-related reactions (IRRs) have been observed with intravenous administration of monoclonal antibodies (see section 4.8 of the SmPC). These reactions may be severe or life-threatening. If an IRR occurs, the infusion may be interrupted, slowed or stopped.
Adverse Reactions
The most common adverse reactions were hypersensitivity reactions (2%) and infusion-related reactions (1%). The most serious adverse reaction was anaphylaxis (0.05%).
Pregnancy
There are no data from the use of sotrovimab in pregnant women. Animal studies have not been evaluated with respect to reproductive toxicity. In a cross-reactive binding assay using a protein array enriched for human embryofetal proteins, no off-target binding was detected. Since sotrovimab is a human immunoglobulin G (IgG), it has the potential for placental transfer from the mother to the developing fetus. The potential treatment benefit or risk of placental transfer of sotrovimab to the developing fetus is not known. Sotrovimab should be used during pregnancy only if the expected benefit to the mother justifies the potential risk to the fetus.
Lactation
It is not known whether sotrovimab is excreted in human milk or absorbed systemically after ingestion. Administration of sotrovimab while breast-feeding can be considered when clinically indicated.
Sotrovimab in the United States
The following is a summary of information for sotrovimab. Healthcare providers in the US should review the Fact Sheets for information about the authorized use of sotrovimab and mandatory requirements of the Emergency Use Authorization (EUA). Sotrovimab has been authorized by the US FDA for the emergency use described below. Sotrovimab is not FDA-approved for this use.
Sotrovimab is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of sotrovimab under section 564(b)(1) of the Act, 21 USC § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
Authorized Use
The US FDA has issued an EUA to permit the emergency use of the unapproved product sotrovimab for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.
Limitations of Authorized Use
Sotrovimab is not authorized for use in patients:
- who are hospitalized due to COVID-19, OR
- who require oxygen therapy due to COVID-19, OR
- who require an increase in baseline oxygen flow rate due to COVID-19 (in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity)
Benefit of treatment with sotrovimab has not been observed in patients hospitalized due to COVID19. SARS-CoV-2 monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID19 requiring high flow oxygen or mechanical ventilation.
Please see the Food and Drug Administration (FDA) Letter of Authorization, full Fact Sheet for Healthcare Providers and full Fact Sheet for Patients, Parents, and Caregivers.
About the GSK and Vir Collaboration
In April 2020, GSK and Vir entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration uses Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventive options to help address the current COVID-19 pandemic and future outbreaks. The companies will leverage GSK’s expertise in functional genomics and combine their capabilities in CRISPR screening and artificial intelligence to identify anti-coronavirus compounds that target cellular host genes. They will also apply their combined expertise to research SARS-CoV-2 and other coronavirus vaccines.
GSK Commitment to Tackling COVID-19
GSK’s response to COVID-19 has been one of the broadest in the industry, with potential treatments in addition to the Company’s vaccine candidates in development with partner organizations.
GSK is collaborating with several organizations on COVID-19 vaccines by providing access to its adjuvant technology. The Company is working with Sanofi SA, Medicago Inc. and SK bioscience Co., Ltd. to develop adjuvanted, protein-based vaccine candidates, and all are now in Phase 3 clinical trials. The use of an adjuvant can be of particular importance in a pandemic since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and contributing to protecting more people in need.
GSK is also working with mRNA specialist CureVac NV to jointly develop next-generation, optimized mRNA vaccines for COVID-19 with the potential to address multiple emerging variants in one vaccine.
GSK is also exploring treatments for COVID-19 patients, collaborating with Vir Biotechnology to investigate monoclonal antibodies that could be used as therapeutic or preventive options for COVID-19.
Vir’s Commitment to COVID-19
Vir was founded with the mission of addressing the world’s most serious infectious diseases. In 2020, Vir responded rapidly to the COVID-19 pandemic by leveraging our unique scientific insights and industry-leading antibody platform to explore multiple monoclonal antibodies as potential therapeutic or preventive options for COVID-19. Sotrovimab is the first SARS-CoV-2-targeting antibody Vir advanced into the clinic. It was carefully selected for its demonstrated promise in preclinical research, including an anticipated high barrier to resistance and potential ability to both block the virus from entering healthy cells and clear infected cells. Vir is continuing to pursue novel therapeutic and prophylactic solutions to combat SARS-CoV-2 and future coronavirus pandemics, both independently and in collaboration with its partners.
About GSK
GSK is a science-led global healthcare company. For further information please visit www.gsk.com/aboutus.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.
GSK Cautionary Statement Regarding Forward-Looking Statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company’s Annual Report on Form 20-F for 2020, GSK’s 2021 Q3 Results and any impacts of the COVID-19 pandemic.
Vir Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the ability of sotrovimab to treat and/or prevent COVID-19 either through IV or IM administration, Vir’s collaboration with GSK, plans to progress regulatory submissions globally, including with the FDA regarding the existing EUA for sotrovimab, planned discussions with other global regulatory agencies, the timing of availability of clinical data, program updates and data disclosures, the clinical development program for sotrovimab, and the ability of sotrovimab to maintain activity against circulating variants of concern and interest, including Omicron. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, challenges in the treatment of hospitalized patients, difficulties in collaborating with other companies or government agencies, challenges in accessing manufacturing capacity, successful development and/or commercialization of alternative product candidates by Vir’s competitors, changes in expected or existing competition, delays in or disruptions to Vir’s business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
| GSK inquiries:
|
|||
| Media Inquiries: | Tim Foley | +44 (0) 20 8047 5502 | (London) |
| Madeleine Breckon | +44 (0) 20 8047 5502 | (London) | |
| Kristen Neese | +1 804 217 8147 | (Philadelphia) | |
| Kathleen Quinn | +1 202 603 5003 | (Washington DC) | |
| Analyst/Investor Inquiries: | Nick Stone | +44 (0) 7717 618834 | (London) |
| Sonya Ghobrial | +44 (0) 7392 784784 | (Consumer) | |
| James Dodwell | +44 (0) 20 8047 2406 | (London) | |
| Mick Readey | +44 (0) 7990 339653 | (London) | |
| Josh Williams | +44 (0) 7385 415719 | (London) | |
| Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) | |
| Frannie DeFranco | +1 215 751 4855 | (Philadelphia) |
Artificial Intelligence
Latest VIPRE Security Group Email Threat Trends Research Exposes Global Phishing and Malware Threat Landscape
The US, UK, Ireland, and Japan emerge as the main source of spam; manufacturing, government, and IT sectors are most victimized; Pikabot top malware family
LONDON, May 9, 2024 /PRNewswire/ — VIPRE Security Group, a global leader and award-winning cybersecurity, privacy, and data protection company, today released its Q1 2024 Email Threat Trends report, based on an analysis of 1.8 billion emails. The findings reveal the evolving landscape of email-based threats and emerging tactics malicious actors are employing.
The US, UK, Ireland, and Japan top the spam sources listThe report identifies the US as the top source of spam emails globally, followed by the U.K., Ireland, and Japan. The US, UK, and Canada are the top three countries most subjected to email-based attacks.
Attackers aim at the manufacturing sectorThe manufacturing, government, and IT sectors are the most victimized by malicious actors. In Q1 2024, the manufacturing sector suffered 43% of email-based attacks, with the government (15%) and IT (11%) trailing well behind. This is a change from Q1 2023, when attackers targeted the financial (25%), healthcare (22%), and education (15%) sectors most often.
Scams surpassing phishing This research warns that ‘scams’ within the spam category are growing in popularity among cybercriminals, overtaking phishing emails in the first quarter of 2024.
There’s been a notable increase in phishing emails masquerading as communications from Human Resources, falsely claiming to relate to employee benefits, compensation, or insurance within a company. These emails contain malicious attachments in .html or .pdf formats, featuring phishing QR codes that redirect recipients to phishing sites upon scanning.
New phishing trends and techniquesIn email phishing campaigns, 75% of emails leverage links, 24% favor attachments, and 1% use QR codes. Attackers are employing links in phishing emails for URL redirection (54%), compromised websites (22%), and newly created domains (15%).
Emerging tactics employed by cybercriminals to execute phishing attacks include the use of .ics calendar invite and .rtf attachment file formats to trick recipients into opening malicious content.
Malspam links and top malware familyEncouraged by the success of password-oriented phishing emails that use links, cybercriminals are opting for malicious links in malspam emails instead of attachments. Malware is increasingly being hidden in cloud storage platforms such as Google Drive. The use of malware-based emails employing attachments has increased to 22% in Q1 2024, from only 3% in Q1 2023.
Due to the void left by the dismantled Qakbot malware, Pikabot has emerged as the top malware family, with IceID a distant second.
Exploiting software vulnerabilitiesCriminals are exploiting a web application vulnerability, most notably Reflected Cross-Site Scripting (XSS), focusing on the tag attribute “href”, to circumvent detection by using a variety of tactics such as images as the entire email content, encoding URLs, and directing the victim through multiple URLs.
Malicious actors are also finding success with thread hijacking of NTLM (NT LAN Manager), a security protocol used by Microsoft Windows operating systems for authentication. By hijacking the authentication thread, attackers extract NTLM challenge-response hashes from legitimate SMB (Server Message Block) sessions, to enable them to impersonate authenticated users and gain unauthorized access.
“Criminals are using email with success to scam, infiltrate networks, and unleash malicious payloads,” warns Usman Choudhary, Chief Product and Technology Officer, VIPRE Security Group. “We’re witnessing bad actors relentlessly exploiting human vulnerabilities and software flaws, circumventing email gateways and security measures with alarming precision. Robust email and endpoint defenses, coupled with a vigilant human frontline, remain our strongest defense against these unyielding attacks.”
To read the full report, click here: VIPRE’s Email Threat Trends Report: Q1 2024.
VIPRE leverages its unique understanding of email security to equip organizations with the information they need to protect themselves. This report is based on proprietary intelligence gleaned from round-the-clock vigilance of the cybersecurity landscape.
About VIPRE Security Group VIPRE Security Group, part of Ziff Davis, Inc., is a leading provider of internet security solutions purpose-built to protect businesses, solution providers, and home users from costly and malicious cyber threats. With over 25 years of industry expertise, VIPRE is one of the world’s largest threat intelligence clouds, delivering exceptional protection against today’s most aggressive online threats. Our award-winning software portfolio includes next-generation antivirus endpoint cloud solutions, advanced email security products, along with threat intelligence for real-time malware analysis, and security awareness training for compliance and risk management. VIPRE solutions deliver easy-to-use, comprehensive layered defense through cloud-based and server security, with mobile interfaces that enable instant threat response. VIPRE is a proud Advanced Technology Partner of Amazon Web Services operating globally across North America and Europe.
The group operates under various brands, including VIPRE®, StrongVPN®, IPVanish®, Inspired eLearning®, Livedrive®, and SugarSync®. www.VIPRE.com
View original content:https://www.prnewswire.co.uk/news-releases/latest-vipre-security-group-email-threat-trends-research-exposes-global-phishing-and-malware-threat-landscape-302141052.html
Artificial Intelligence
Logicalis unites Australia and Asia operations as Logicalis Asia Pacific, creating a regional powerhouse
LONDON, May 9, 2024 /PRNewswire/ — Logicalis, a leading global technology services provider, has announced the creation of a new Asia Pacific entity, combining its Logicalis Australia and Logicalis Asia operations. This strategic realignment will be effective from June 01, 2024, and positions Logicalis to amplify its market presence through increased synergy within the APAC region.
The combined Logicalis Asia Pacific entity will consolidate 1,600 employees with a collective revenue upwards of $US350 million across 10 countries, including Singapore, Malaysia, Hong Kong, China, Thailand, Indonesia, Taiwan, Philippines, Vietnam, and now Australia. The newly formed entity will be led by Chong-Win Lee as the Chief Executive Officer (CEO) of Logicalis Asia Pacific with Anthony Woodward continuing in his role as CEO of Logicalis Australia and reporting to Chong-Win Lee. In addition to his current responsibilities, Woodward will lead a special task force focused on fostering innovation and identifying synergistic, joint opportunities across the region.
Chong-Win Lee, CEO, Logicalis APAC, said, “The strategic consolidation of Logicalis’ operations across Australia and Asia marks a pivotal moment in the company’s continued growth and evolution. The aim of this reorganisation is to build a powerhouse capable of delivering high-impact technology solutions more efficiently for customers across Asia Pacific, while still providing the local expertise and support that Logicalis customers value.”
The combination is designed to enhance service delivery and bring a cohesive solution portfolio to customers, reflecting the alignment of Logicalis Asia’s strategy to enable XaaS operating models to support digital transformation, and Logicalis Australia’s commitment to becoming the best MSP in the country. The combined operation will deliver seamless access to Logicalis’ experience in industry sectors such as financial services, government and healthcare, empowering teams to build skill and capacity for data and application modernisation, cloud managed services, artificial intelligence (AI), and more. From a security perspective, it will reinforce the company’s powerful customer proposition, giving customers access to the global network of threat intelligence research and experience encapsulated in the regional Logicalis Security Operations Centre (SOC).
Anthony Woodward, CEO, Logicalis Australia, said, “Formally combining the strengths of Logicalis Australia and its Asia counterparts is an acceleration of what has already been happening organically. This evolution lets Logicalis Australia and our customers leverage high-value digital capabilities from across the region, ensuring faster, more competitive, and more comprehensive service offerings. It also strengthens the local team’s onshore capabilities while integrating best practices and expertise from across Asia, enabling the delivery of scalable, cost-effective managed service options for customers.”
The announcement comes at a time when Logicalis has been increasingly focusing on expanding its core Microsoft and Cisco businesses, enhancing its capabilities in cloud, cybersecurity, and managed services. Logicalis Asia has also recently brought Atlassian onboard as a strategic vendor. Chong-Win Lee, CEO, Logicalis Asia Pacific, said, “The Logicalis Asia Pacific entity will help the company to achieve greater influence with vendors and deliver even greater outcomes for customers into the future.”
Bob Bailkoski, global CEO, Logicalis said, “The goal for Logicalis is clear: to harness the collective strengths of the company’s diverse operations to drive innovation and growth throughout Australia, Asia, and the globe. This reorganisation represents a strategic response to the evolving IT landscape and reinforces Logicalis’ commitment to developing solutions that support its customers’ success in the digital age.”
About Logicalis
We are Architects of Change™. We help organisations succeed in a digital-first world. At Logicalis, we harness our collective technology expertise to help our clients build a blueprint for success, so they can deliver sustainable outcomes that matter.
Our lifecycle services across cloud, connectivity, collaboration, and security are designed to help optimise operations, reduce risk and empower employees.
As a global technology service provider, we deliver next-generation digital managed services, to provide our clients with real-time visibility and actionable insights across the performance of their digital ecosystem including; availability, user experience, security, economic performance and sustainability.
Our 7000+ ‘Architects of Change’ are based in 30 territories around the globe, helping our 10,000+ clients across a range of industry sectors create sustainable outcomes through technology.
Logicalis has annualised revenues of $1.7 billion, from operations in Europe, North America, Latin America, Asia Pacific, and Africa.
It is a division of Datatec Limited, listed on the Johannesburg Stock Exchange, with revenues of over $5.1 billion.
For more information visit https://www.logicalis.com
For media enquiries, contact:
Logicalis Team at Another Word
Email: [email protected]
Tel: 020 3176 0014
View original content:https://www.prnewswire.co.uk/news-releases/logicalis-unites-australia-and-asia-operations-as-logicalis-asia-pacific-creating-a-regional-powerhouse-302141050.html
ROME, May 9, 2024 /PRNewswire/ — Raiinmaker, a Web3 and AI Technology company that has developed the Raiinmaker AI Super App and Raiinmaker Network is revolutionizing the monetization of users’ contribution to AI infrastructure. Today, Yield App proudly announced that an exclusive $200,000 allocation of Raiinmaker’s native token, $COIIN, will be the second-ever offering on its Angel Launchpad!
Established in 2018, Raiinmaker is on a mission to empower anyone with a smartphone anywhere in the world, to earn cryptocurrency through training AI models and running an independent validator node. By leveraging groundbreaking Web3 and AI technology, Raiinmaker provides a decentralized platform for AI developers and validators to collaborate securely and exchange AI models.
Validators on Raiinmaker earn rewards for their contributions, fostering a culture of active engagement and top-tier performance. The platform operates on a transparent governance framework, allowing community members to play a pivotal role in decision-making processes.
Raiinmaker’s token and platform are designed with interoperability in mind, ensuring seamless integration with major blockchain networks. The Raiinmaker Network Protocol harnesses decentralized AI and scalable Web3 infrastructure to redefine the value associated with identity, data, and behavior. Built on this network, Raiinmaker’s Super App is set to transform how users monetize their contributions to AI infrastructure via the platform’s native token, $COIIN.
Raiinmaker’s team is composed of industry veterans from corporate giants such as Disney, Oracle and Boeing. With a wealth of experience and a shared passion for innovation, this team is driving Raiinmaker’s mission to revolutionize the digital landscape.
“We’re excited to be the second project with our native token, $COIIN, as an offering on the Yield App Angel Launchpad and we share the same vision of providing investment opportunities for crypto enthusiasts,” said J.D. Seraphine, Founder and CEO of Raiinmaker.
Raiinmaker’s $COIIN token will be offered on the Yield App Angel Launchpad on 9 May 2024. To prepare for launch day, Yield App users can ensure they have a positive USDT balance in their Yield App wallet. This will be used for token allocation during the pledge period.
Before making their pledge, Yield App users must also have Gold tier, Diamond tier, or Angel status. This can be achieved by staking YLD on the Yield App platform. For more details on YLD and the loyalty program, visit the YLD page on Yield App’s website.
With Angel status, users enjoy exclusive benefits such as guaranteed minimum allocation on each Launchpad launch and no maximum pledge cap. Plus, Angel status includes all the benefits of Diamond tier, including top rates on all products. Users can now unlock unlimited access to Angel Launchpad by buying Lifetime Angel status with a one-time fee of 50,000 YLD or by staking 100,000 YLD.
During the pledge period, participants will need to submit a Base Protocol (BASE) address to receive their token allocation, paving the way for a seamless user experience.
“We are thrilled to welcome Raiinmaker and their innovative $COIIN token to the Yield App Angel Launchpad,” said Tim Frost, CEO of Yield App. “Our second Launchpad offering aligns with our vision of empowering users in the digital asset space, and opens up an exciting opportunity for our users with Gold tier, Diamond tier, or Angel status.”
For more updates on the official offering of $COIIN token, visit the Yield App Angel Launchpad website.
About Raiinmaker
Raiinmaker is a Web3 and AI Technology Company that has developed the Raiinmaker AI Super App and Raiinmaker Network Protocol, which revolutionizes the monetization of users’ contribution to AI infrastructure.
About Yield App
Yield App is a digital wealth platform that serves as a digital wealth partner to its customers. The company’s mission is to provide safe custody for digital assets and enable users to exchange and earn at market-leading rates. Yield App achieves this through its innovative technology that seamlessly bridges traditional and decentralized finance, offering users a more efficient and user-friendly way to manage their portfolios.
Photo – https://mma.prnewswire.com/media/2407560/Raiinmaker_x_Angel_Launchpad_1280x720.jpg
Logo – https://mma.prnewswire.com/media/2407862/Logo_Horizontal_Colours_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/raiinmaker-to-make-a-splash-on-yield-app-angel-launchpad-302140022.html
-
Artificial Intelligence6 days agoCleverTap launches Clever.AI, the AI-Driven Edge for Customer Engagement & Retention
-
Uncategorized6 days agoImproving the Developer Journey in Crafting Artificial Intelligence Applications
-
Uncategorized6 days ago
Unveiling the Complex Psychological Implications of Artificial Intelligence
-
Artificial Intelligence6 days ago5G Enterprise Market Projected to Reach $115.81 billion by 2030 – Exclusive Report by 360iResearch
-
Artificial Intelligence6 days agoBitrue expands Bitcoin Runes Offerings with GPTV Listing and Staking Options
-
Artificial Intelligence7 days agoVirtual Assistant Market Size to Grow USD 8613.5 Million by 2030 at a CAGR of 22.3% | Valuates Reports
-
Artificial Intelligence6 days agoInnodisk Introduces iCAP Air: Advancing Air Quality Management through Autonomous Decision-Making
-
Artificial Intelligence6 days agoAppian Named a Leader in the 2024 Gartner® Magic Quadrant™ for Process Mining Platforms Report
